Abstract
To date the optimal antiviral treatment against severe coronavirus disease 2019 (COVID-19) has not been proven; remdesivir is a promising drug with in vitro activity against several viruses, but in COVID-19 the clinical results are currently not definitive. In this retrospective observational study, we analyzed the clinical outcomes (survival analysis, efficacy, and safety) in a group of hospitalized patients with COVID-19 treated with remdesivir in comparison with a control group of patients treated with other antiviral or supportive therapies. We included 163 patients treated with remdesivir and 403 subjects in the control group; the baseline characteristics were similar in the two groups; the mortality rate was higher in the control group (24.8% vs. 2.4%, p < 0.001), the risk of intensive care unit (ICU) admission was higher in the control group (17.8% vs. 9.8%, p = 0.008); hospitalization time was significantly lower in patients treated with remdesivir (9.5 vs. 12.5 days, p < 0.001). The safety of remdesivir was good and no significant adverse events were reported. In multivariate analysis, the remdesivir treatment was independently associated with a 34% lower mortality rate (odds ratio = 0.669; p = 0.014). In this analysis, the treatment with remdesivir was associated with lower mortality, lower rate of ICU admission, and shorter time of hospitalization. No adverse events were observed. This promising antiviral treatment should also be confirmed by other studies.
Keywords: COVID-19; SARS-CoV-2; antiviral therapy; hospitalization; remdesivir.
【저자키워드】 COVID-19, SARS-CoV-2, antiviral therapy, Hospitalization, remdesivir., 【초록키워드】 Treatment, coronavirus disease, viruses, antiviral therapy, Coronavirus disease 2019, Efficacy, intensive care, Antiviral, intensive care unit, Remdesivir, risk, Antiviral treatment, hospitalized patients, observational study, clinical outcomes, ICU, Clinical outcome, adverse events, survival, adverse event, ICU admission, mortality rate, Admission, Multivariate analysis, retrospective, in vitro activity, Analysis, survival analysis, Odds ratio, supportive therapies, control group, two groups, baseline characteristics, severe coronavirus disease, subject, lower mortality, significantly lower, analyzed, reported, treated, hospitalized patient, patients treated, with COVID-19, 【제목키워드】 Treatment, case-control study, affected, hospitalized patient,